Ilya’s Pharma Receives Approval from Swedish Regulators to Initiate Phase II Clinical Study of ILP100 Gene Therapy to Treat Difficult Wound Patients with Diabetes
Follows highly promising Phase I results from on-site production and delivery of key chemokine CXCL12 by transformed lactic acid bacteria for accelerated wound healing. Uppsala, June 23, 2021: Ilya Pharma, a clinical stage gene therapy company today announced that it has received approval from the Swedish Medical Product Agency and Swedish Ethical Review Authority to initiate a Phase II clinical study of its ILP100 gene therapy for the treatment of difficult diabetic wounds (EudraCT 2021-000563-69). ILP100h has recently been assigned the INN name emilimogene sigulactibac by the WHO and